PLoS ONE (Jan 2020)

Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis.

  • Julie Gorham,
  • Anthony Moreau,
  • Francis Corazza,
  • Lorenzo Peluso,
  • Fanny Ponthieux,
  • Marta Talamonti,
  • Antonio Izzi,
  • Carole Nagant,
  • Narcisse Ndieugnou Djangang,
  • Alessandra Garufi,
  • Jacques Creteur,
  • Fabio Silvio Taccone

DOI
https://doi.org/10.1371/journal.pone.0244628
Journal volume & issue
Vol. 15, no. 12
p. e0244628

Abstract

Read online

IntroductionCoronavirus disease 2019 (COVID-19) appeared in China in December 2019 and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients suggest that a cytokine storm may play a major role in the pathophysiology and are considered as a relevant parameter in predicting most severe course of disease. The aim of this study was to assess repeated IL-6 levels in critically ill COVID-19 patients admitted to our Intensive Care Unit (ICU) and to evaluate their relationship with patient's severity and outcome.MethodsWe conducted a retrospective study on patients admitted to the ICU with a diagnosis of COVID-19 between March 10 (i.e. the date of the first admitted patients) and April 30, 2020. Demographic, clinical and laboratory data were collected at admission. On the day of IL-6 blood concentration measurement, we also collected results of D-Dimers, C-Reactive Protein, white blood cells and lymphocytes count, lactate dehydrogenase (LDH) and ferritin as well as microbiological samples, whenever present.ResultsOf a total of 65 patients with COVID-19 admitted to our ICU we included 41 patients with repeated measure of IL-6. There was a significant difference in IL-6 levels between survivors and non-survivors over time (p = 0.001); moreover, non survivors had a significantly higher IL-6 maximal value when compared to survivors (720 [349-2116] vs. 336 [195-646] pg/mL, p = 0.01). The IL-6 maximal value had a significant predictive value of ICU mortality (AUROC 0.73 [95% CI 0.57-0.89]; p = 0.01).ConclusionsRepeated measurements of IL-6 can help clinicians in identifying critically ill COVID-19 patients with the highest risk of poor prognosis.